期刊文献+

重组人血管内皮抑制素联合化疗治疗晚期胃癌临床观察 被引量:2

Clinical observation of recombinant human endostatin combined with chemotherapy for advanced gastric cancer
下载PDF
导出
摘要 目的探讨重组人血管内皮抑制素与化疗药物(奥沙利铂+替吉奥胶囊)联合治疗晚期胃癌的有效性和安全性。方法 21例二线复治的晚期胃癌患者接受重组人血管内皮抑制素联合化疗药物治疗,化疗后评价疗效和毒性。结果全组21例共完成治疗周期86个,获得完全缓解(CR)1例,部分缓解(PR)8例,稳定(SD)7例,病情进展(PD)5例,有效率(PR)42.9%,生活质量(QOL)改善率76.2%。主要毒副反应包括骨髓抑制和消化道反应,未见明显心血管系统毒性和出血情况。结论重组人血管内皮抑制素联合化疗治疗晚期胃癌患者具有较好疗效,不增加化疗毒性,耐受性好,值得临床推广应用。 Objective To study the efficacy and safety of recombinant human endostatin(Oxaliplatin+Gio capsules)combined treatment in advanced gastric cancer.Methods Twenty-one cases of second-line retreatment of advanced gastric cancer patients received recombinant human endostatin combined with chemotherapy drugs.The efficacy and toxicity after chemotherapy were evaluated.Results All 21 patients completed a total of 86 treatment cycles,among which,there was 1 case of CR,8 cases of PR,7 cases of SD,and 5 cases of PD.PR was 42.9%,and QOL improvement rate was 76.2%.Main side effects included bone marrow suppression and gastrointestinal reactions and there were no significant cardiovascular toxicity and bleeding.Conclusion Recombinant human endostatin combined with chemotherapy for advanced gastric cancer patients has a good effect.It does not increase the toxicity of chemotherapy and it is well tolerated.Therefore it is worthy of clinical application.
出处 《实用临床医药杂志》 CAS 2011年第17期105-106,118,共3页 Journal of Clinical Medicine in Practice
关键词 胃癌 重组人血管内皮抑制素 化疗 联合治疗 gastric cancer recombinant human endostatin chemotherapy combination therapy
  • 相关文献

参考文献9

  • 1陈书瑾,徐伟,丁霞,姜霖.紫杉醇、5-氟脲嘧啶联合奥沙利铂治疗晚期胃癌的观察与护理[J].实用临床医药杂志(护理版),2010,14(4):7-8. 被引量:5
  • 2Woell E,GreilR,Eisterer W,et al.Oxaliplatin,irinotecan and cetuxinab in advanced gastric cancer,First efficacy results of a muliticenter phase Ⅱ trial (AGMT Gastric-2) of the Arbeitsgeme in schaft Medikam entoese Tum ortherapie (AGMT)[C].ASCO Meeting,2009,27:a4538.
  • 3Yeh K,Hsu C,Lin C,et al.PhaseⅡ study of cetuxin ab plus weekly cisplatin and 24-hour infusion of higlrdose 5-fluorou racil and leucovorin for the first line treatment of adcanced gastric cancer[C].ASCO Meeting,2009,27:a4567.
  • 4Fahke,J,Ridwelski K,Fbrsduetz A,et al.Ceruxin ab plus docetaxel-cisplatin(DC)as first-line treatment for locally advanced or metastatic gastric cancer Prelininary results of a phase Ⅱ study[C].ASCO Meeting,2009,27:a15592.
  • 5Folkman J.Mtiangonenesis in cancer therapy endostain and its mechanisms of cution[J].Expt cell Res,2006,312(6):594.
  • 6李青峰,赵前锋,张娟,龚先齐.NP方案联合恩度治疗复治晚期NSCLC的近期疗效与CEA水平[J].海南医学院学报,2010,16(1):57-59. 被引量:8
  • 7江丰收,王刚,孙玉蓓,姚艺伟,季楚舒,胡冰.重组人血管内皮抑素联合XELOX方案治疗晚期胃癌的临床观察[J].肿瘤,2009,29(8):790-792. 被引量:17
  • 8AI-Batran S,Harmann J T,Probst S,et al.A randomized phase Ⅲ trial in patients with advanced adenocarcinoma of the stomach receiving first-time chemotherapy with fluorouracil,leucovorin and oxaliplatin (FLO) versus fluorouracil,leucovorin and cisplatin (FLP):2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition)[C].J Clin Oncol,2006,24(18s):LBA4016.
  • 9Koizumi W,Tzkiuchi H,Yamada Y,et al.Phase Ⅱ study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer(G-SOX study)[J].Ann Oncol,2010,21(5):1001.

二级参考文献24

共引文献27

同被引文献18

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部